ARTICLE | Company News
J&J, Merck sales and marketing update
October 11, 2010 7:00 AM UTC
Johnson & Johnson's Janssen Pharmaceutical Companies subsidiary will regain worldwide marketing rights to cancer drug Caelyx doxorubicin from Merck after a 1996 deal expires at year end. The drug is ...